Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2024-04-28 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于修改公司章程修订对照表
Governance Information Classification · 100% confidence The document is a detailed announcement regarding amendments to the company's articles of association (公司章程). It includes specific changes to governance rules, shareholder rights, board and independent director qualifications, and procedures for meetings and resolutions. The content is focused on corporate governance structure and internal rules rather than financial performance or audit results. There is no indication of financial statements, audit opinions, or earnings data. The document is lengthy (15,000 characters) and contains detailed governance provisions, which aligns with a Governance Information report. Therefore, the document should be classified as Governance Information (CGR).
2024-04-28 Chinese
关于中山爱护日用品有限公司业绩承诺实现情况说明的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 康芝药业股份有限公司 regarding the performance commitment fulfillment of 中山爱护日用品有限公司, which the company acquired. It details the background of the acquisition, the performance commitments made by the controlling shareholder, the actual performance results audited by an accounting firm, and the triggering of the share repurchase clause due to underperformance. The document includes board and supervisory committee opinions and resolutions related to this matter. It is not a full financial report, earnings release, or audit report by itself, but rather an announcement about the status and implications of a prior agreement and audit results. The document length is 3434 characters, relatively short, and it serves as a formal disclosure of a significant corporate event related to performance commitments and share repurchase obligations. This fits best under Regulatory Filings (RNS), as it is a regulatory announcement about a corporate event and related audit findings, not the audit report itself or a financial report.
2024-04-28 Chinese
2023年度独立董事述职报告（吴清和）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of a company, covering the director's duties, attendance at board and shareholder meetings, opinions on various company matters including financial reports, internal controls, related party transactions, appointment of auditors and senior management, and stock incentive plans during the 2023 fiscal year. It references compliance with laws and regulations, and discusses the director's oversight and supervisory role. The document is not a financial report itself but a formal report on the independent director's activities and opinions for the year. This type of document fits the category of Board/Management Information (MANG), as it relates to governance and management oversight rather than financial results or regulatory filings. The document length (7350 characters) and content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2024-04-28 Chinese
内部审计工作细则（2024年度修订）
Regulatory Filings Classification · 95% confidence The document is titled '内部审计工作细则' which translates to 'Internal Audit Work Rules' for 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It details the internal audit management, audit evidence, working papers, and archive management procedures. It is a regulatory or procedural document outlining internal audit policies and responsibilities rather than a financial report or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement since it is substantive and detailed. It is not a certification or officer attestation. The document fits best under Regulatory Filings (RNS) as it is a compliance and internal control related filing that does not fit other categories.
2024-04-28 Chinese
康芝药业股份有限公司2023年年审会计师履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年年审会计师履职情况评估报告' which translates to '2023 Annual Auditor Performance Evaluation Report'. It details the evaluation of the auditing firm 中审众环会计师事务所 for the year 2023, including their qualifications, independence, quality control, and audit procedures. The content focuses on the auditor's performance and compliance with regulatory standards rather than presenting the company's financial statements or full annual report. The document length is 4046 characters, which is relatively short and focused on audit evaluation rather than the full audit report or annual report. This matches the description of an Audit Report / Information (AR) filing, which includes standalone audit reports and auditor evaluations but excludes full annual reports. Therefore, the document should be classified as AR with high confidence. FY 2023
2024-04-28 Chinese
内部审计工作制度 （2024年度修订）
Governance Information Classification · 95% confidence The document is titled '内部审计工作制度' which translates to 'Internal Audit Work System' and details the internal audit policies, responsibilities, organizational structure, and procedures of the company 康芝药业股份有限公司. It references relevant laws and regulations governing internal audit work and describes the internal audit function's role in governance and control. The document is a policy or procedural document related to internal audit, not a financial report, earnings release, or announcement. It is not a standalone audit report with audit opinions or financial statements, nor is it a regulatory filing or announcement of a report. It is a governance-related document detailing internal audit rules and practices, which fits best under Governance Information (CGR). The document length is 4685 characters, which is substantive and contains detailed governance content rather than a brief announcement or certification. Therefore, the most appropriate classification is Governance Information (CGR).
2024-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.